These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29790573)

  • 1. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Ruck T; Pfeuffer S; Schulte-Mecklenbeck A; Gross CC; Lindner M; Metze D; Ehrchen J; Sondermann W; Pul R; Kleinschnitz C; Wiendl H; Meuth SG; Klotz L
    Neurology; 2018 Dec; 91(24):e2233-e2237. PubMed ID: 30404783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease.
    Alcalá C; Pzére-Miralles F; Gascón F; Evole M; Estutia M; Gil-Perotín S; Casanova B
    Mult Scler Relat Disord; 2019 Jan; 27():406-408. PubMed ID: 30530069
    [No Abstract]   [Full Text] [Related]  

  • 4. Alemtuzumab for the treatment of multiple sclerosis.
    Evan JR; Bozkurt SB; Thomas NC; Bagnato F
    Expert Opin Biol Ther; 2018 Mar; 18(3):323-334. PubMed ID: 29309202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 6. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 7. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Willis MD; Harding KE; Pickersgill TP; Wardle M; Pearson OR; Scolding NJ; Smee J; Robertson NP
    Mult Scler; 2016 Aug; 22(9):1215-23. PubMed ID: 26514979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Carandini T; Pietroboni AM; Sacchi L; De Riz MA; Pozzato M; Arighi A; Fumagalli GG; Martinelli Boneschi F; Galimberti D; Scarpini E
    Mult Scler; 2020 Sep; 26(10):1268-1269. PubMed ID: 32463329
    [No Abstract]   [Full Text] [Related]  

  • 10. Mortality from Listeria monocytogenes meningoencephalitis following escalation to alemtuzumab therapy for relapsing-remitting Multiple Sclerosis.
    Canham LJW; Manara A; Fawcett J; Rolinski M; Mortimer A; Inglis KEA; Cottrell DA
    Mult Scler Relat Disord; 2018 Aug; 24():38-41. PubMed ID: 29885597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab.
    Nerrant E; Thouvenot E; Castelnovo G
    Rev Neurol (Paris); 2017 Mar; 173(3):175-176. PubMed ID: 28320519
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of B Cell Profile for Predicting Secondary Autoimmunity in Patients Treated With Alemtuzumab.
    Walo-Delgado PE; Monreal E; Medina S; Quintana E; Sainz de la Maza S; Fernández-Velasco JI; Lapuente P; Comabella M; Ramió-Torrentà L; Montalban X; Midaglia L; Villarrubia N; Carrasco-Sayalero A; Rodríguez-Martín E; Roldán E; Meca-Lallana J; Alvarez-Lafuente R; Masjuan J; Costa-Frossard L; Villar LM
    Front Immunol; 2021; 12():760546. PubMed ID: 34691084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous CMV and
    Pappolla A; Midaglia L; Boix Rodríguez CP; Puig AA; Lung M; Camps IR; Castilló J; Mulero P; Vidal-Jordana A; Arrambide G; Rodriguez-Acevedo B; Sastre-Garriga J; Río J; Comabella M; Galán I; Tintoré M; Montalbán X
    Neurology; 2019 Feb; 92(6):296-298. PubMed ID: 30587519
    [No Abstract]   [Full Text] [Related]  

  • 14. Dominus effect: challenging complications of alemtuzumab-related thyroid autoimmunity.
    Bianco A; Nicoletti T; Traini E; Del Giacomo P; Del Gatto V; Lucchini M; Rota CA; Mirabella M
    J Endocrinol Invest; 2020 Aug; 43(8):1159-1161. PubMed ID: 32130689
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis.
    Ferraro D; Camera V; Vitetta F; Zennaro M; Ciolli L; Nichelli PF; Sola P
    Neurology; 2018 May; 90(18):852-854. PubMed ID: 29602915
    [No Abstract]   [Full Text] [Related]  

  • 16. Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ.
    Pfeuffer S
    Mult Scler; 2018 Nov; 24(13):1783-1784. PubMed ID: 30307361
    [No Abstract]   [Full Text] [Related]  

  • 17. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility.
    Montgomery SM; Kusel J; Nicholas R; Adlard N
    J Med Econ; 2017 Sep; 20(9):962-973. PubMed ID: 28635362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disseminated necrotizing leukoencephalopathy eight months after alemtuzumab treatment for multiple sclerosis.
    Metz I; Rieckmann P; Kallmann BA; Brück W
    Acta Neuropathol Commun; 2016 Aug; 4(1):81. PubMed ID: 27503238
    [No Abstract]   [Full Text] [Related]  

  • 20. Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
    John N; Carroll A; Brownlee WJ; Chataway J
    J Neurol Neurosurg Psychiatry; 2019 Dec; 90(12):1376-1378. PubMed ID: 31079064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.